Peter F. Billingsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter F. Billingsley has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- Stephen L. Hoffman
Sanaria Inc., Rockville, Maryland, USA
22 shared publications - Thomas Richie
Sanaria Inc., Rockville, USA
18 shared publications - Claudia Daubenberger
Swiss Tropical and Public Health Institute, Allschwil, Switzerland
11 shared publications - Eric. R. James
Sanaria Inc
11 shared publications - Salim Abdulla
Ifakara Health Institute, Dar es Salaam, Tanzania
11 shared publications - B. Kim Lee Sim
Sanaria Inc., Rockville, Maryland, USA
10 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Safety and Efficacy of Two Attenuated PfSPZ Vaccines in Malaria Inexperienced Soldiers Exposed to Plasmodium Falciparum Malaria Genetically Distant from the Vaccine Strain during Deployment to Papua Province, Indonesia
Background: Two partially protective Plasmodium falciparum (Pf) subunit malaria vaccines are reducing disease burden in African children. However, no malaria vaccine is licensed for travelers. We assessed the safety and vaccine efficacy (VE) against Pf malaria of two live-attenuated Pf sporozoite (PfSPZ) vaccines in malaria-inexperienced Indonesian soldiers during the first 24 weeks of deployment to Papua Province, Indonesia, where Pf parasites are highly divergent from the West African vaccine strain, thereby requiring cross strain VE.Methods: In this double blind, placebo-controlled trial, healthy soldiers were randomized 1.0 : 0.5 : 1.0: 0.5 to radiation-attenuated PfSPZ Vaccine (9x105 PfSPZ/dose, days 1, 8, 29), normal saline (NS) (days 1, 8, 29), chemo-attenuated PfSPZ-CVac (chloroquine) (2x105 PfSPZ/dose, days 1, 29, 57) or NS (chloroquine) (days 1, 29, 57) at their malaria-free homebase in Sumatra. Unblinded pharmacists preparing indistinguishable vaccine and NS syringes had no participant contact. PfSPZ-CVac (chloroquine) and NS (chloroquine) participants received weekly doses of chloroquine during immunization. During the 46 week deployment, thick blood smears were performed every four weeks and whenever a soldier experienced malaria-compatible symptoms. VE (1 – hazard ratio) against first Pf clinical malaria during 24 weeks of surveillance in participants who received three doses of investigational product was a primary endpoint. Surveillance continued until departure from Papua and then for 24 weeks post departure, at which point the database was analyzed by independent statisticians. Missing data were not replaced. Clinicaltrials.gov: NCT03503058.Results: 379 soldiers screened and 345 received at least one injection from June 11 to September 18, 2022. For vaccinees and controls, rates and severity of adverse events within 7 (PfSPZ Vaccine) or 6 (PfSPZ-CVac) days of injection were similar except for increased subjective fever in PfSPZ Vaccine recipients. During the period of transient parasitemia, 7-9 days post first immunization only, PfSPZ-CVac recipients had symptoms of malaria. 335 soldiers deployed and 334 began surveillance in Papua. One soldier was excluded due to Pf infection prior to deployment. At 24 weeks of surveillance, ~8 months post immunization, 47/111 (42.3%) placebo, 24/109 (22.0%) PfSPZ Vaccine, and 27/113 (23.9%) PfSPZ-CVac recipients experienced first Pf clinical malaria. VEs against Pf clinical malaria / Pf infection were 56% (95%CI: 0.28, 0.73) / 54% (0.26, 0.72) for PfSPZ Vaccine and 50% (0.19, 0.69) / 50% (0.19, 0.69) for PfSPZ-CVac (CQ). There was no protection against P. vivax.Interpretation: PfSPZ Vaccine and PfSPZ-CVac (chloroquine) provided 50-56% VE in malaria inexperienced soldiers for ~8 months post immunization against Pf clinical malaria and infection, indicating PfSPZ vaccines could serve as partially efficacious traveler’s vaccines that protect against highly variant Pf strains.
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSafety and Efficacy of Two Attenuated PfSPZ Vaccines in Malaria Inexperienced Soldiers Exposed to Plasmodium Falciparum Malaria Genetically Distant from the Vaccine Strain during Deployment to Papua Province, Indonesia
Background: Two partially protective Plasmodium falciparum (Pf) subunit malaria vaccines are reducing disease burden in African children. However, no malaria vaccine is licensed for travelers. We assessed the safety and vaccine efficacy (VE) against Pf malaria of two live-attenuated Pf sporozoite (PfSPZ) vaccines in malaria-inexperienced Indonesian soldiers during the first 24 weeks of deployment to Papua Province, Indonesia, where Pf parasites are highly divergent from the West African vaccine strain, thereby requiring cross strain VE.Methods: In this double blind, placebo-controlled trial, healthy soldiers were randomized 1.0 : 0.5 : 1.0: 0.5 to radiation-attenuated PfSPZ Vaccine (9x105 PfSPZ/dose, days 1, 8, 29), normal saline (NS) (days 1, 8, 29), chemo-attenuated PfSPZ-CVac (chloroquine) (2x105 PfSPZ/dose, days 1, 29, 57) or NS (chloroquine) (days 1, 29, 57) at their malaria-free homebase in Sumatra. Unblinded pharmacists preparing indistinguishable vaccine and NS syringes had no participant contact. PfSPZ-CVac (chloroquine) and NS (chloroquine) participants received weekly doses of chloroquine during immunization. During the 46 week deployment, thick blood smears were performed every four weeks and whenever a soldier experienced malaria-compatible symptoms. VE (1 – hazard ratio) against first Pf clinical malaria during 24 weeks of surveillance in participants who received three doses of investigational product was a primary endpoint. Surveillance continued until departure from Papua and then for 24 weeks post departure, at which point the database was analyzed by independent statisticians. Missing data were not replaced. Clinicaltrials.gov: NCT03503058.Results: 379 soldiers screened and 345 received at least one injection from June 11 to September 18, 2022. For vaccinees and controls, rates and severity of adverse events within 7 (PfSPZ Vaccine) or 6 (PfSPZ-CVac) days of injection were similar except for increased subjective fever in PfSPZ Vaccine recipients. During the period of transient parasitemia, 7-9 days post first immunization only, PfSPZ-CVac recipients had symptoms of malaria. 335 soldiers deployed and 334 began surveillance in Papua. One soldier was excluded due to Pf infection prior to deployment. At 24 weeks of surveillance, ~8 months post immunization, 47/111 (42.3%) placebo, 24/109 (22.0%) PfSPZ Vaccine, and 27/113 (23.9%) PfSPZ-CVac recipients experienced first Pf clinical malaria. VEs against Pf clinical malaria / Pf infection were 56% (95%CI: 0.28, 0.73) / 54% (0.26, 0.72) for PfSPZ Vaccine and 50% (0.19, 0.69) / 50% (0.19, 0.69) for PfSPZ-CVac (CQ). There was no protection against P. vivax.Interpretation: PfSPZ Vaccine and PfSPZ-CVac (chloroquine) provided 50-56% VE in malaria inexperienced soldiers for ~8 months post immunization against Pf clinical malaria and infection, indicating PfSPZ vaccines could serve as partially efficacious traveler’s vaccines that protect against highly variant Pf strains.
- Open Access
- 29 September 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (11) , 2875-2900
Complete attenuation of Plasmodium falciparum sporozoites by atovaquone–proguanil
To develop a Plasmodium falciparum (Pf) vaccine that precludes replication inside the host for improved vaccine safety, we tested chemo-attenuation (CVac) of sporozoites (SPZ) with atovaquone–proguanil (AP). In mice, P. berghei sporozoites administered with AP invaded hepatocytes, arrested early, and induced robust protection, which correlated with parasite-specific effector-memory CD8+ T cell responses. In a clinical trial of PfSPZ-CVac (AP), in which three doses of 5.12 × 10 4 or 1.5 × 10 5 PfSPZ were administered by direct venous inoculation combined with oral single-dose AP (1000/400 mg), blood stage infections were fully prevented during immunisation. 2/8 and 2/10 of vaccinees, respectively, were protected when challenged with 3.2 × 10 3 PfSPZ 10 weeks later, inferior to PfSPZ-CVac (chloroquine/CQ) that allows in-host replication. Comparative analysis of responses to 228 Pf proteins revealed that protection with PfSPZ-CVac (CQ) was associated with antibodies to two liver-stage antigens (LISP2, LSA1) and a multi-stage antigen (PfMSP5), but not to the major surface protein PfCSP. The complete arrest of high numbers of Pf sporozoites by single-dose AP should allow a significant dose-frequency reduction of the current daily AP malaria chemoprophylaxis regimen.
- 29 September 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (11) , 2875-2900
Open AccessComplete attenuation of Plasmodium falciparum sporozoites by atovaquone–proguanil
To develop a Plasmodium falciparum (Pf) vaccine that precludes replication inside the host for improved vaccine safety, we tested chemo-attenuation (CVac) of sporozoites (SPZ) with atovaquone–proguanil (AP). In mice, P. berghei sporozoites administered with AP invaded hepatocytes, arrested early, and induced robust protection, which correlated with parasite-specific effector-memory CD8+ T cell responses. In a clinical trial of PfSPZ-CVac (AP), in which three doses of 5.12 × 10 4 or 1.5 × 10 5 PfSPZ were administered by direct venous inoculation combined with oral single-dose AP (1000/400 mg), blood stage infections were fully prevented during immunisation. 2/8 and 2/10 of vaccinees, respectively, were protected when challenged with 3.2 × 10 3 PfSPZ 10 weeks later, inferior to PfSPZ-CVac (chloroquine/CQ) that allows in-host replication. Comparative analysis of responses to 228 Pf proteins revealed that protection with PfSPZ-CVac (CQ) was associated with antibodies to two liver-stage antigens (LISP2, LSA1) and a multi-stage antigen (PfMSP5), but not to the major surface protein PfCSP. The complete arrest of high numbers of Pf sporozoites by single-dose AP should allow a significant dose-frequency reduction of the current daily AP malaria chemoprophylaxis regimen.
- Open Access
- 4 June 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (6) , 1364-1377
Assessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea
: A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions in malaria prevalence; however, progress subsequently stalled, leading to a proposal to develop and implement a highly effective malaria vaccine to increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum (P. falciparum) sporozite vaccines against P. falciparum malaria, which demonstrated safety and efficacy, a larger phase 3 trial was planned to support vaccine licensure for specific target populations and eventual island-wide malaria elimination. The Equatorial Guinea Pilot Study for Recruitment, Screening and Participant Registry (EGRESPAR) assessed the health status of the target population and generated a registry of eligible children and adults. Households in areas with malaria prevalence ≥15% were randomly selected, aiming to register 2,100 healthy Equatoguineans divided equally into age groups of 1.5–9, 10–17, and 18–50 years. A total of 6,493 individuals from 1,807 households, who considered themselves or their children to be healthy, completed questionnaires; 2,021 were screened using phase 3 enrollment criteria, 643 were excluded, and 1,378 were entered into the registry. Among those screened, 13.6% had Plasmodium, 1.8% had Loa loa, 4.8% had hepatitis B, 0.5% had hepatitis C, and 2.1% had HIV. Adults were twice as likely to have clinically relevant medical conditions, such as obesity, hypertension, or diabetes, meeting exclusion criteria compared to children. In conclusion, there was a significant prevalence of infections and chronic medical conditions among Bioko Island residents who considered themselves or their children to be healthy and interested in clinical research participation, particularly in adults. The EGRESPAR successfully generated a registry to support the initiation of a large-scale phase 3 vaccine trial.
- 4 June 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (6) , 1364-1377
Open AccessAssessment of Health Status and Creation of a Registry of Potential Research Participants Aged 1.5 to 50 Years on Bioko Island, Equatorial Guinea
: A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions in malaria prevalence; however, progress subsequently stalled, leading to a proposal to develop and implement a highly effective malaria vaccine to increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum (P. falciparum) sporozite vaccines against P. falciparum malaria, which demonstrated safety and efficacy, a larger phase 3 trial was planned to support vaccine licensure for specific target populations and eventual island-wide malaria elimination. The Equatorial Guinea Pilot Study for Recruitment, Screening and Participant Registry (EGRESPAR) assessed the health status of the target population and generated a registry of eligible children and adults. Households in areas with malaria prevalence ≥15% were randomly selected, aiming to register 2,100 healthy Equatoguineans divided equally into age groups of 1.5–9, 10–17, and 18–50 years. A total of 6,493 individuals from 1,807 households, who considered themselves or their children to be healthy, completed questionnaires; 2,021 were screened using phase 3 enrollment criteria, 643 were excluded, and 1,378 were entered into the registry. Among those screened, 13.6% had Plasmodium, 1.8% had Loa loa, 4.8% had hepatitis B, 0.5% had hepatitis C, and 2.1% had HIV. Adults were twice as likely to have clinically relevant medical conditions, such as obesity, hypertension, or diabetes, meeting exclusion criteria compared to children. In conclusion, there was a significant prevalence of infections and chronic medical conditions among Bioko Island residents who considered themselves or their children to be healthy and interested in clinical research participation, particularly in adults. The EGRESPAR successfully generated a registry to support the initiation of a large-scale phase 3 vaccine trial.
- Open Access
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Repeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms
Resistance to clinical malaria takes years to develop even in hyperendemic regions and sterilizing immunity has rarely been observed. To evaluate the maturation of the host response against controlled repeat exposures to P. falciparum (Pf) NF54 strain-infected mosquitoes, we systematically monitored malaria-naïve participants through an initial exposure to uninfected mosquitoes and 4 subsequent homologous exposures to Pf-infected mosquitoes over 21 months (n = 8 males) (ClinicalTrials.gov# NCT03014258). The primary outcome was to determine whether protective immunity against parasite infection develops following repeat CHMI and the secondary outcomes were to track the clinical signs and symptoms of malaria and anti-Pf antibody development following repeat CHMI. After two exposures, time to blood stage patency increases significantly and the number of reported symptoms decreases indicating the development of clinical tolerance. The time to patency correlates positively with both anti-Pf circumsporozoite protein (CSP) IgG and CD8 + CD69+ effector memory T cell levels consistent with partial pre-erythrocytic immunity. IFNγ levels decrease significantly during the participants’ second exposure to high blood stage parasitemia and could contribute to the decrease in symptoms. In contrast, CD4-CD8 + T cells expressing CXCR5 and the inhibitory receptor, PD-1, increase significantly after subsequent Pf exposures, possibly dampening the memory response and interfering with the generation of robust sterilizing immunity.
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessRepeat controlled human Plasmodium falciparum infections delay bloodstream patency and reduce symptoms
Resistance to clinical malaria takes years to develop even in hyperendemic regions and sterilizing immunity has rarely been observed. To evaluate the maturation of the host response against controlled repeat exposures to P. falciparum (Pf) NF54 strain-infected mosquitoes, we systematically monitored malaria-naïve participants through an initial exposure to uninfected mosquitoes and 4 subsequent homologous exposures to Pf-infected mosquitoes over 21 months (n = 8 males) (ClinicalTrials.gov# NCT03014258). The primary outcome was to determine whether protective immunity against parasite infection develops following repeat CHMI and the secondary outcomes were to track the clinical signs and symptoms of malaria and anti-Pf antibody development following repeat CHMI. After two exposures, time to blood stage patency increases significantly and the number of reported symptoms decreases indicating the development of clinical tolerance. The time to patency correlates positively with both anti-Pf circumsporozoite protein (CSP) IgG and CD8 + CD69+ effector memory T cell levels consistent with partial pre-erythrocytic immunity. IFNγ levels decrease significantly during the participants’ second exposure to high blood stage parasitemia and could contribute to the decrease in symptoms. In contrast, CD4-CD8 + T cells expressing CXCR5 and the inhibitory receptor, PD-1, increase significantly after subsequent Pf exposures, possibly dampening the memory response and interfering with the generation of robust sterilizing immunity.
- 5 April 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (5) , 362-366
A paradigm for Africa-centric vaccine development in Equatorial Guinea
- 5 April 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (5) , 362-366
A paradigm for Africa-centric vaccine development in Equatorial Guinea
- Open Access
- 9 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (6)
Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults
BACKGROUND: Sanaria PfSPZ Vaccine, composed of attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), protects against malaria. We conducted this clinical trial to assess the safety and efficacy of PfSPZ Vaccine in HIV-positive (HIV + ) individuals, since the HIV-infection status of participants in mass vaccination programs may be unknown. METHODS: This randomized, double-blind, placebo-controlled trial enrolled 18- to 45-year-old HIV-negative (HIV – ) and well-controlled HIV + Tanzanians (HIV viral load 500 cells/μL). Participants received 5 doses of PfSPZ Vaccine or normal saline (NS) over 28 days, followed by controlled human malaria infection (CHMI) 3 weeks later. RESULTS: There were no solicited adverse events in the 9 HIV – and 12 HIV + participants. After CHMI, 6 of 6 NS controls, 1 of 5 HIV – vaccinees, and 4 of 4 HIV + vaccinees were Pf positive by quantitative PCR (qPCR). After immunization, anti–Pf circumsporozoite protein (anti-PfCSP) (isotype and IgG subclass) and anti-PfSPZ antibodies, anti-PfSPZ CD4 + T cell responses, and Vδ2 + γδ CD3 + T cells were nonsignificantly higher in HIV – than in HIV + vaccinees. Sera from HIV – vaccinees had significantly higher inhibition of PfSPZ invasion of hepatocytes in vitro and antibody-dependent complement deposition (ADCD) and Fcγ3B binding by anti-PfCSP and ADCD by anti–cell-traversal protein for ookinetes and SPZ (anti-PfCelTOS) antibodies. CONCLUSIONS: PfSPZ Vaccine was safe and well tolerated in HIV + vaccinees, but not protective. Vaccine efficacy was 80% in HIV – vaccinees ( P = 0.012), whose sera had significantly higher inhibition of PfSPZ invasion of hepatocytes and enrichment of multifunctional PfCSP antibodies. A more potent PfSPZ vaccine or regimen is needed to protect those living with HIV against Pf infection in Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT03420053. FUNDING: Equatorial Guinea Malaria Vaccine Initiative (EGMVI), made up of the Government of Equatorial Guinea Ministries of Mines and Hydrocarbons, and Health and Social Welfare, Marathon Equatorial Guinea Production Limited, Noble Energy, Atlantic Methanol Production Company, and EG LNG; Swiss government, through ESKAS scholarship grant no. 2016.0056; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH; NIH grant 1U01AI155354-01.
- 9 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (6)
Open AccessSafety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults
BACKGROUND: Sanaria PfSPZ Vaccine, composed of attenuated Plasmodium falciparum (Pf) sporozoites (SPZ), protects against malaria. We conducted this clinical trial to assess the safety and efficacy of PfSPZ Vaccine in HIV-positive (HIV + ) individuals, since the HIV-infection status of participants in mass vaccination programs may be unknown. METHODS: This randomized, double-blind, placebo-controlled trial enrolled 18- to 45-year-old HIV-negative (HIV – ) and well-controlled HIV + Tanzanians (HIV viral load 500 cells/μL). Participants received 5 doses of PfSPZ Vaccine or normal saline (NS) over 28 days, followed by controlled human malaria infection (CHMI) 3 weeks later. RESULTS: There were no solicited adverse events in the 9 HIV – and 12 HIV + participants. After CHMI, 6 of 6 NS controls, 1 of 5 HIV – vaccinees, and 4 of 4 HIV + vaccinees were Pf positive by quantitative PCR (qPCR). After immunization, anti–Pf circumsporozoite protein (anti-PfCSP) (isotype and IgG subclass) and anti-PfSPZ antibodies, anti-PfSPZ CD4 + T cell responses, and Vδ2 + γδ CD3 + T cells were nonsignificantly higher in HIV – than in HIV + vaccinees. Sera from HIV – vaccinees had significantly higher inhibition of PfSPZ invasion of hepatocytes in vitro and antibody-dependent complement deposition (ADCD) and Fcγ3B binding by anti-PfCSP and ADCD by anti–cell-traversal protein for ookinetes and SPZ (anti-PfCelTOS) antibodies. CONCLUSIONS: PfSPZ Vaccine was safe and well tolerated in HIV + vaccinees, but not protective. Vaccine efficacy was 80% in HIV – vaccinees ( P = 0.012), whose sera had significantly higher inhibition of PfSPZ invasion of hepatocytes and enrichment of multifunctional PfCSP antibodies. A more potent PfSPZ vaccine or regimen is needed to protect those living with HIV against Pf infection in Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT03420053. FUNDING: Equatorial Guinea Malaria Vaccine Initiative (EGMVI), made up of the Government of Equatorial Guinea Ministries of Mines and Hydrocarbons, and Health and Social Welfare, Marathon Equatorial Guinea Production Limited, Noble Energy, Atlantic Methanol Production Company, and EG LNG; Swiss government, through ESKAS scholarship grant no. 2016.0056; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH; NIH grant 1U01AI155354-01.
- Open Access
- 11 August 2023
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 22 (1) , 964-1007
Sporozoite immunization: innovative translational science to support the fight against malaria
1. This review is written by the developers of Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines (vaccines comprised of live, metabolically active SPZ) and by researchers who have generated the ...
- 11 August 2023
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 22 (1) , 964-1007
Open AccessSporozoite immunization: innovative translational science to support the fight against malaria
1. This review is written by the developers of Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines (vaccines comprised of live, metabolically active SPZ) and by researchers who have generated the ...
- Open Access
- 9 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (1) , 138-146
Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults
: The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 106 or 2.7 × 106 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group (P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.
- 9 May 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (1) , 138-146
Open AccessSafety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults
: The radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) Vaccine has demonstrated safety and immunogenicity in 5-month-old to 50-year-old Africans in multiple trials. Except for one, each trial has restricted enrollment to either infants and children or adults < 50 years old. This trial was conducted in Equatorial Guinea and assessed the safety, tolerability, and immunogenicity of three direct venous inoculations of 1.8 × 106 or 2.7 × 106 PfSPZ, of PfSPZ Vaccine, or normal saline administered at 8-week intervals in a randomized, double-blind, placebo-controlled trial stratified by age (6–11 months and 1–5, 6–10, 11–17, 18–35, and 36–61 years). All doses were successfully administered. In all, 192/207 injections (93%) in those aged 6–61 years were rated as causing no or mild pain. There were no significant differences in solicited adverse events (AEs) between vaccinees and controls in any age group (P ≥ 0.17). There were no significant differences between vaccinees and controls with respect to the rates or severity of unsolicited AEs or laboratory abnormalities. Development of antibodies to P. falciparum circumsporozoite protein occurred in 67/69 vaccinees (97%) and 0/15 controls. Median antibody levels were highest in infants and 1–5-year-olds and declined progressively with age. Antibody responses in children were greater than in adults protected against controlled human malaria infection. Robust immunogenicity, combined with a benign AE profile, indicates children are an ideal target for immunization with PfSPZ Vaccine.
- 7 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (674) , eabj3776
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria
A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen. Safety, immunogenicity, and VE of a three-dose regimen were assessed in adults in Balonghin, Burkina Faso in a two-component study: an open-label dose escalation trial with 32 participants followed by a double-blind, randomized, placebo-controlled trial (RCT) with 80 participants randomized to receive three doses of 2.7 × 10 6 PfSPZ ( N = 39) or normal saline ( N = 41) just before malaria season. To clear parasitemia, artesunate monotherapy was administered before first and last vaccinations. Thick blood smear microscopy was performed on samples collected during illness and every 4 weeks for 72 weeks after last vaccinations, including two 6-month malaria transmission seasons. Safety outcomes were assessed in all 80 participants who received at least one dose and VE for 79 participants who received three vaccinations. Myalgia was the only symptom that differed between groups. VE (1 − risk ratio; primary VE endpoint) was 38% at 6 months ( P = 0.017) and 15% at 18 months (0.078). VE (1 − hazard ratio) was 48% and 46% at 6 and 18 months ( P = 0.061 and 0.018). Two weeks after the last dose, antibodies to P. falciparum circumsporozoite protein and PfSPZ were higher in protected versus unprotected vaccinees. A three-dose regimen of PfSPZ Vaccine demonstrated safety and efficacy against malaria infection in malaria-experienced adults.
- 7 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (674) , eabj3776
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria
A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen. Safety, immunogenicity, and VE of a three-dose regimen were assessed in adults in Balonghin, Burkina Faso in a two-component study: an open-label dose escalation trial with 32 participants followed by a double-blind, randomized, placebo-controlled trial (RCT) with 80 participants randomized to receive three doses of 2.7 × 10 6 PfSPZ ( N = 39) or normal saline ( N = 41) just before malaria season. To clear parasitemia, artesunate monotherapy was administered before first and last vaccinations. Thick blood smear microscopy was performed on samples collected during illness and every 4 weeks for 72 weeks after last vaccinations, including two 6-month malaria transmission seasons. Safety outcomes were assessed in all 80 participants who received at least one dose and VE for 79 participants who received three vaccinations. Myalgia was the only symptom that differed between groups. VE (1 − risk ratio; primary VE endpoint) was 38% at 6 months ( P = 0.017) and 15% at 18 months (0.078). VE (1 − hazard ratio) was 48% and 46% at 6 and 18 months ( P = 0.061 and 0.018). Two weeks after the last dose, antibodies to P. falciparum circumsporozoite protein and PfSPZ were higher in protected versus unprotected vaccinees. A three-dose regimen of PfSPZ Vaccine demonstrated safety and efficacy against malaria infection in malaria-experienced adults.
- 7 December 2022
- Published by Springer Nature in Nature
- Vol. 612 (7940) , 534-539
In vitro production of infectious Plasmodium falciparum sporozoites
- 7 December 2022
- Published by Springer Nature in Nature
- Vol. 612 (7940) , 534-539
In vitro production of infectious Plasmodium falciparum sporozoites